GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4 Therapeutics Inc (NAS:CCCC) » Definitions » Net Change in Cash

C4 Therapeutics (C4 Therapeutics) Net Change in Cash : $40.35 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is C4 Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

C4 Therapeutics's Net Change in Cash for the three months ended in Mar. 2024 was $-36.93 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $40.35 Mil.

C4 Therapeutics Net Change in Cash Historical Data

The historical data trend for C4 Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics Net Change in Cash Chart

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial 54.24 91.18 -104.90 -46.37 97.00

C4 Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.72 -4.60 16.27 65.61 -36.93

C4 Therapeutics Net Change in Cash Calculation

C4 Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-106.838+158.349+45.489+0
=97.00

C4 Therapeutics's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-18.118+-53.396+34.583+0
=-36.93

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C4 Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of C4 Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

C4 Therapeutics (C4 Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4 Therapeutics Inc (NAS:CCCC) » Definitions » Net Change in Cash
Comparable Companies
CTMX KOD ACXP ANVS CLDI VTGN ORMP CSBR STTK OMER OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
Website
https://www.c4therapeutics.com
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
Executives
Mark Mossler officer: Chief Accounting Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Kendra Adams officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Leonard Reyno officer: Chief Medical Officer 607 NORTH LAS PALMAS AVENUE, LOS ANGELES CA 90004
Utpal Koppikar director C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Laura Bessen director 4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Andrew Hirsch director, officer: See Remarks C/O BIND THERAPEUTICS, INC., 325 VASSAR ST, CAMBRIDGE MA 02139
Kelly Schick officer: Chief People Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott N Boyle officer: Chief Business Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Malcolm Salter director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Adam Crystal officer: Chief Medical Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Elena Prokupets director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel officer: Chief Legal Officer C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher officer: Chief Scientific Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Lauren White officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472

C4 Therapeutics (C4 Therapeutics) Headlines

From GuruFocus

C4 Therapeutics Inc (CCCC) Reports Q3 2023 Financial Results and Business Highlights

By GuruFocus Research • 11-01-2023

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

By sperokesalga sperokesalga • 02-23-2023

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC� Degrader of EGFR L858R for NSCLC

By sperokesalga sperokesalga • 05-30-2023

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

By Stock market mentor Stock market mentor • 02-08-2023

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC� Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC� Degrader in Development for Multiple Myelom

By Marketwired • 10-11-2023

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

By sperokesalga sperokesalga • 04-19-2023

C4 Therapeutics Announces Chief Financial Officer Succession

By Marketwired • 09-05-2023

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC� Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

By GuruFocusNews GuruFocusNews • 06-25-2022

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC� Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

By GuruFocusNews GuruFocusNews • 06-05-2022

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

By Marketwired • 08-08-2023